Transcranial Magnetic Stimulation (TMS)

Transcranial magnetic stimulation (TMS) uses time-varying magnetic fields to non-invasively stimulate brain tissue, generating action potentials in cortical neurons without skin contact pain. Initially developed as a diagnostic tool (motor evoked potentials, central motor conduction time), TMS has expanded into both diagnostic neurophysiology and therapeutic neuropsychiatry — with FDA-approved indications for treatment-resistant depression, OCD, smoking cessation, and migraine. This page covers the principles of TMS, diagnostic applications, therapeutic rTMS protocols, and the integration into modern clinical neurology.

Principles of TMS

Mechanism

• Brief, intense electrical current in a coil generates a rapidly changing magnetic field.
• The magnetic field penetrates skull and scalp without attenuation.
• Induces an electrical current in the underlying cortex (electromagnetic induction).
• The induced current depolarizes cortical neurons, particularly interneurons that transynaptically activate pyramidal cells.

Stimulation Targets

• Motor cortex: produces measurable peripheral muscle response (MEP).
• Other cortical areas: produces functional changes (language disruption, mood change, perception alteration).
• Subcortical structures: less directly accessible.

Coil Types

• Circular coil: broader field; older standard.
• Figure-of-eight coil: focal stimulation; most common clinical use.
• Deep TMS (H-coil): deeper penetration; FDA-approved for some indications.
• Coil orientation determines current direction in cortex.

Diagnostic TMS

Motor Evoked Potentials

• Single TMS pulse over motor cortex.
• Measure motor response from peripheral muscle (e.g., abductor pollicis brevis for hand cortex).
• Tests corticospinal tract integrity.

Resting Motor Threshold (RMT)

• Lowest TMS intensity that produces measurable MEP in 50% of trials.
• Quantifies corticospinal excitability.
• Elevated in: stroke, multiple sclerosis, ALS.
• Decreased in: epilepsy.

Central Motor Conduction Time (CMCT)

• MEP latency from cortex to muscle minus peripheral motor conduction time.
• Tests corticospinal tract conduction.
• Normal CMCT: ~6–9 ms (upper extremity), ~16–22 ms (lower extremity).
• Prolonged in:
  • Multiple sclerosis (corticospinal tract demyelination).
  • ALS (UMN involvement).
  • Cervical myelopathy.
  • Spinal cord injury.

Cortical Mapping

• Multiple TMS pulses at different scalp locations to map motor cortex.
• Used preoperatively for tumor surgery planning.
• Less invasive than direct cortical stimulation.

Triple Stimulation Technique (TST)

• Specialized technique combining cortical and peripheral stimulation.
• More sensitive than standard MEP for subtle abnormalities.
• Useful when standard MEP normal but clinical suspicion remains.

Clinical Applications (Diagnostic)

Multiple Sclerosis

• Prolonged CMCT supports upper motor neuron involvement.
• Useful when other testing is borderline.
• Combined with VEP and SSEP for comprehensive demyelination assessment.

ALS

• Prolonged CMCT supports UMN involvement.
• Helps meet Awaji criteria for ALS diagnosis.
• Particularly useful in cases without clinical UMN findings.

Cervical Myelopathy

• Prolonged CMCT to upper extremity.
• Helps confirm clinical findings.
• Surgical planning.

Stroke

• RMT changes correlate with motor recovery.
• Research tool for stroke recovery assessment.

Cortical Excitability in Epilepsy

• Reduced RMT.
• Reduced cortical inhibition (paired-pulse TMS).
• Research and emerging clinical applications.

Therapeutic TMS (rTMS)

Mechanism

• Repetitive pulses over hours/days produce lasting changes in cortical excitability.
• Low frequency (≤1 Hz): inhibitory.
• High frequency (≥5 Hz): excitatory.
• Theta burst stimulation: more rapid protocol with lasting effects.
• Likely mechanisms: LTP/LTD-like changes, glutamatergic and GABAergic modulation, network effects.

FDA-Approved Therapeutic Indications

• Treatment-resistant depression (2008): high-frequency over left DLPFC.
• OCD (2018): deep TMS over medial prefrontal/cingulate.
• Smoking cessation (2020): deep TMS over insula/PFC.
• Migraine (2014): single-pulse TMS for acute migraine.
• Anxiety + depression: deep TMS approved 2021.

Depression Protocol

• Targets: left dorsolateral prefrontal cortex (DLPFC).
• Stimulation: 10 Hz, 75 trains of 40 stimuli each, total 3000 pulses per session.
• Session duration: 30–40 minutes.
• Schedule: daily (5 days/week) for 4–6 weeks.
• Response rate: ~50%.
• Remission rate: ~30%.
• Maintenance sessions sometimes used.

Theta Burst Stimulation (TBS)

• 3-pulse bursts at 50 Hz, repeated at 5 Hz.
• iTBS (intermittent): excitatory.
• cTBS (continuous): inhibitory.
• Sessions only 3–6 minutes vs 30–40 for standard.
• Approved for depression; non-inferior to standard protocol.

Side Effects

• Local discomfort at stimulation site.
• Headache.
• Facial twitching during stimulation.
• Rare: seizure (especially with epilepsy history); <1% in healthy.
• Hearing protection used (clicking sound).

Contraindications

• Metal in head (except dental).
• Cochlear implants.
• Cardiac pacemakers (relative).
• Active seizure disorder (relative).
• Pregnancy (caution).

Other Therapeutic Applications (Off-Label or Research)

• Chronic pain: motor cortex stimulation.
• Aphasia post-stroke: language cortex stimulation.
• Schizophrenia: temporal cortex (auditory hallucinations).
• PTSD: prefrontal cortex.
• Bipolar depression.
• Parkinson disease: motor cortex.
• Spasticity, dystonia.
• Tinnitus.

Advanced TMS Techniques

Paired-Pulse TMS

• Two pulses delivered close together.
• Tests intracortical inhibition and facilitation.
• Short-interval intracortical inhibition (SICI): tests GABA-A.
• Long-interval intracortical inhibition (LICI): tests GABA-B.
• Intracortical facilitation (ICF): tests glutamatergic.
• Research and emerging diagnostic applications.

Neuronavigated TMS

• MRI-guided precise coil placement.
• Increases reproducibility and accuracy.
• Standard for therapeutic protocols.

Concurrent TMS-EEG

• Records EEG response to TMS pulses.
• TMS-evoked potentials (TEPs).
• Research tool for cortical reactivity assessment.

Safety Considerations

• Seizure risk: very low in healthy; higher with active epilepsy.
• Stimulation parameters: keep within published safety guidelines.
• Coil cooling: prevents overheating.
• Patient screening: medical history, seizure risk factors, metal exposure.
• Trained operator essential.

Comparison: TMS vs Other Brain Stimulation

🔍 Did You Know?

The development of transcranial magnetic stimulation as a treatment for treatment-resistant depression represents one of the most consequential applications of neurophysiology in clinical psychiatry. After failure of multiple antidepressant trials, patients with treatment-resistant depression historically had limited options — ECT (effective but with cognitive side effects), vagus nerve stimulation (modest benefit), or experimental medications. rTMS provides a non-invasive alternative with minimal side effects and substantial response rates: in well-selected patients, approximately 50% achieve clinically significant response and 30% achieve remission, even after multiple antidepressant failures. The protocol is intensive (30–40 minutes daily for 4–6 weeks), but the side effect profile is minimal — local discomfort, occasional headache, and very rare seizure. The FDA approval in 2008 for treatment-resistant depression, expanded approvals for OCD (2018), smoking cessation (2020), and migraine (2014), represent a transformation: brain stimulation is now standard psychiatric practice, integrated with pharmacotherapy and psychotherapy. The lesson generalizes: understanding cortical neurophysiology has produced effective neuropsychiatric treatments without requiring molecular targets. For practicing neurologists and psychiatrists, the take-home is that patients with treatment-resistant depression should be referred for rTMS evaluation when appropriate. The technology continues to evolve: theta burst stimulation reduces session time to 3-6 minutes, deep TMS reaches mood-relevant circuits, and accelerated protocols compress treatment courses. The neurophysiology of clinical neurology and clinical psychiatry are converging, and rTMS is at the leading edge of this integration.

Pitfalls and Pearls

• TMS mechanism: magnetic field induces electrical current in cortex; trans-synaptic activation of pyramidal cells.
• Figure-8 coil: standard focal stimulation.
• Deep TMS (H-coil): deeper penetration for some FDA indications.
• Resting motor threshold (RMT): quantifies corticospinal excitability.
• Central motor conduction time (CMCT): tests corticospinal tract; prolonged in MS, ALS, myelopathy.
• Diagnostic TMS: MS, ALS, cervical myelopathy, spinal cord injury.
• rTMS for depression: FDA-approved 2008; ~50% response, ~30% remission.
• Standard depression protocol: 10 Hz left DLPFC, 3000 pulses, 30–40 min daily for 4–6 weeks.
• Theta burst stimulation: 3–6 min sessions; non-inferior to standard.
• Depression target: left DLPFC (high-frequency excitatory).
• OCD approval 2018: deep TMS over medial PFC/cingulate.
• Migraine 2014: single-pulse TMS for acute treatment.
• Smoking cessation 2020: deep TMS over insula/PFC.
• Seizure risk: very low in healthy; higher in active epilepsy.
• Contraindications: metal in head (except dental), cochlear implants, pacemakers.
• Paired-pulse TMS: tests cortical inhibition (GABA-A, GABA-B) and facilitation.
• Neuronavigation: MRI-guided coil placement; increases precision.
• TMS expanding: integrated with pharmacotherapy and psychotherapy in modern psychiatry.

References

1. Rossi S, Hallett M, Rossini PM, Pascual-Leone A. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol. 2009;120(12):2008-2039.
2. O’Reardon JP, Solvason HB, Janicak PG, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression. Biol Psychiatry. 2007;62(11):1208-1216.
3. Lefaucheur JP, Aleman A, Baeken C, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): an update (2014-2018). Clin Neurophysiol. 2020;131(2):474-528.
4. Carmi L, Tendler A, Bystritsky A, et al. Efficacy and safety of deep transcranial magnetic stimulation for obsessive-compulsive disorder: a prospective multicenter randomized double-blind placebo-controlled trial. Am J Psychiatry. 2019;176(11):931-938.
5. Lipton RB, Dodick DW, Silberstein SD, et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol. 2010;9(4):373-380.
6. Cole EJ, Stimpson KH, Bentzley BS, et al. Stanford accelerated intelligent neuromodulation therapy for treatment-resistant depression. Am J Psychiatry. 2020;177(8):716-726.